| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We examined whether APOBEC3B as a viral defense mechanism contributes to carcinogenesis in childhood leukemia. The frequency of APOBEC3B gene expression in pediatric leukemia samples was low, but C→T mutations were found in 50% of cases, regardless of APOBEC3B gene expression. In addition, cord blood-derived CD34-positive cells into which the shRNA of the IKAROS gene and the PAX5 gene and the TEL-AML1 fusion gene were introduced, respectively, and part of the APOBEC3B gene simultaneously expressed showed cloned proliferation. The clone was found to have reduced differentiation ability, enhanced self-renewal ability and reduced apoptosis. These results suggest that the APOBEC3B gene may contribute to leukemic transformation of pediatric preleukemic clones.
|
